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ardiac Arrhythmias: The Quest for a Cure
Historical Perspective
ein J. J. Wellens, MD, FACC
aastricht, the Netherlands
During the last 40 years, much progress has been made in our understanding and
management of cardiac arrhythmias. A major step in the late 1960s was to combine
programmed electrical stimulation of the heart with intracardiac activation recording. This
allowed: 1) localization of the site of the block in the atrioventricular conduction system in
patients with bradycardia; and 2) identification of the site of origin and the mechanism of
supraventricular and ventricular tachycardia. Combining information from intracardiac
studies with findings on the 12-lead electrocardiogram (ECG) resulted in much better
localization of conduction abnormalities and arrhythmias using the ECG. This new
knowledge led to the development of new therapies, such as bradycardia and antitachycardia
pacing, and surgery for supraventricular and ventricular tachycardia. A very important
development in the treatment of life-threatening arrhythmias was the implantable defibril-
lator. Growing concern about failure to protect patients at risk for dying suddenly with
antiarrhythmic drugs led to a rapid increase in their number. Cure by catheter ablation
became possible for patients with different types of arrhythmias. Genetic analysis allowed the
identification of different monogenic arrhythmic diseases. Several challenges remain: the
epidemic of atrial fibrillation, arrhythmias in heart failure, and sudden death out-of-hospital.
One-fifth of all deaths are sudden and unexpected. The important issue is how we are going
to prevent these unnecessary deaths from occurring. (J Am Coll Cardiol 2004;44:1155–63)
© 2004 by the American College of Cardiology Foundationi
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he birth of clinical electrophysiology. A major break-
hrough in our understanding of cardiac arrhythmias came
n the late 1960s when a reliable recording of the electro-
ram of the His bundle and programmed electrical stimu-
ation of the heart became available for clinical use. The
ackground for these developments came from the work of
ioneers such as Hecht, Latour, Puech, and Giraud who, in
he 1940s to 1950s, showed that intracardiac catheters could
e used to record electrical activity inside the heart and to
ap cardiac activation (1–3). In 1958, Furman and Robin-
on (4) showed that the heart could be stimulated by
onnecting an intracardiac catheter to a stimulator.
After proof by Durrer and Roos (5) that in Wolff-
arkinson-White (WPW) syndrome two connections exist
etween the atrium and ventricle, it was a logical develop-
ent to try to initiate the clinically occurring tachycardias in
he WPW patient by programmed electrical stimulation of
he heart. This was done in Amsterdam when, in patients
ith WPW syndrome, intracardiac catheters were placed at
ifferent locations in the heart allowing the recording of
lectrical activity at those sites. By connecting the intracar-
iac catheters to a versatile stimulator, it was possible to
erform programmed electrical stimulation at different sites
From the Cardiovascular Research Institute, Maastricht, the Netherlands. Pre-
ented, in part, at the Third International Lecture of the American College of
ardiology in New Orleans, Louisiana, on March 9, 2004.aManuscript received May 4, 2004, accepted May 18, 2004.n the heart. It was shown that critically timed premature
timuli resulted in the reproducible initiation and termina-
ion of the clinically documented tachycardias (6). By
ecording during the tachycardia the activation times from
he different intracardiac catheters, it was also possible to
ocalize the site of origin or pathway of the tachycardia.
ndependent from the group in Amsterdam, Coumel et al.
7) in Paris found that they could initiate atrioventricular
unctional tachycardias by timed stimuli. These findings
ere followed by the initiation and termination of different
ypes of supraventricular tachycardias on both sides of the
tlantic (8–12). In 1971, the first book on programmed
lectrical stimulation of the heart in the study of tachycar-
ias was published (13).
In the late 1960s, by making a reproducible recording of
he His bundle electrogram, Scherlag et al. (14) showed that
t was possible to investigate normal and abnormal conduc-
ion over the atrioventricular node-His bundle branch
ystem. Several groups such as those led by Ken Rosen,
nkar Narula, and Paul Puech demonstrated that this
llowed not only accurate localization and risk-stratification
f atrioventricular conduction disturbances, but also a much
etter identification of the pathway of the impulse during
achycardia (15). At that time, almost each electrophysi-
logic study brought new information about the site of
rigin, the pathway, and the mechanism of a tachycardia. It
ecame an important challenge how to use this information
o come to a clinically useful classification of tachycardias
nd how to identify the different types correctly when
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Cardiac Arrhythmias: The Quest for a Cure September 15, 2004:1155–63ooking at the 12-lead electrocardiogram (ECG) (16). This
as especially important in the presence of a widened QRS
omplex during tachycardia. In the early 1970s, it was
hown that, also in patients with a ventricular tachycardia,
he arrhythmia could reproducibly be initiated and termi-
ated by programmed electrical stimulation of the heart (17)
Figs. 1 and 2). That allowed the identification of the ECG
haracteristics diagnostic for a ventricular tachycardia, a
nding of obvious importance not only for a correct diag-
osis but also because of therapeutic and prognostic conse-
uences. Together with earlier observations by Sandler and
Abbreviations and Acronyms
CAST  Cardiac Arrhythmia Suppression Trial
ECG  electrocardiogram
HF  heart failure
LBBB  left bundle branch block
LV  left ventricular
MADIT  Multicenter Automatic Defibrillator
Implantation Trial
SCD-HeFT  Sudden Cardiac Death in Heart Failure
Trial
WPW  Wolff-Parkinson-White
igure 1. A programmed ventricular stimulation study done during the ea
how the reproducible initiation of a ventricular tachycardia by single vent
f 700 ms. As shown, ventricular premature beats given in the interval rang
eats given later than 500 ms or earlier then 410 ms do not create the
achycardia.arriott (18), those findings allowed the correct diagnosis
f a ventricular tachycardia based on presence or absence of
relation between atrial and ventricular events and the
idth, the frontal plane axis, and configurational character-
stics of the QRS complex during tachycardia (19). By
orrelating the information from programmed electrical
timulation of the heart with the findings on the 12-lead
CG, it now became possible to correctly classify all the
ifferent types of clinically occurring tachycardias as to their
ite of origin or pathway, their clinical presentation (parox-
smal, incessant), and their mechanism (re-entry or a focal
rigin) (20).
he development of new therapies. ARRHYTHMIA SUR-
ERY. The demonstration that in WPW syndrome an extra
onnection between the atrium and the ventricle plays a
ivotal role in the tachycardia mechanism made Cobb et al.
21) decide to cure such a patient by interrupting the extra
onnection surgically. Since then, the Duke group (22),
oth cardiologically (Dr. Gallagher) and surgically (Drs.
ealy and Cox), played an important role in our understand-
ng of WPW syndrome and the development of surgical
herapy. Arrhythmia surgeons such as Drs. Sealy, Guirau-
on (23), Cox, and Harken played an important role in our
70s. The selected extra and intracardiac electrograms in the four panels
premature beats during right ventricular pacing with a basic cycle length
to 410 ms result in the initiation of the ventricular tachycardia. Premature
itions required for initiation and maintenance of a reentrant ventricularrly 19
ricular
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September 15, 2004:1155–63 Cardiac Arrhythmias: The Quest for a Curenderstanding of cardiac arrhythmias and their treatment.
his was again demonstrated when Josephson et al. (24,25)
howed in patients with ventricular tachycardias that accu-
ate localization of the area of abnormal impulse formation
ould be followed by cure from the arrhythmia when the
bnormal area was excised surgically. Cox et al. (26) showed
hat atrial fibrillation (AF) could be controlled by making
everal incisions in the atria, thereby preventing the mech-
nism responsible for the arrhythmia.
NTITACHYCARDIA PACING. Originally, the pacemaker was
device that provided a fixed rate ventricular rhythm in
atients with (intermittent) bradycardia. However, imme-
iately after the demonstration that re-entrant tachycardias
ould be terminated reproducibly by critically timed stimuli,
his principle was applied by (implantable) pacing tech-
iques in patients with tachycardias. Already in 1968, Ryan
t al. (27) used “underdrive” pacing for that purpose. In the
ears that followed, growing sophistication occurred using
achycardia terminating and preventing algorithms (28).
HE IMPLANTABLE DEFIBRILLATOR. Mirowski and Mower
29) deserve credit for their pioneering role in the develop-
ent of an implantable automatic defibrillator to rescue
atients from life-threatening ventricular arrhythmias. Ma-
or advances in technology resulted in increasing effective-
ess and widespread acceptance of the device (30), to such
n extent, as will be discussed later, that the implantable
efibrillator now threatens the limits of our medical finan-
ial budget!
ATHETER ABLATION. The possibility of localizing the site
f origin or the pathway of a tachycardia using catheter
echniques led to the application of ablative energy at that
ite. Originally, high-energy shocks were given to interrupt
igure 2. Same patient as Figure 1. A critically timed premature beat inv
irculating impulse resulting in termination of the ventricular tachycardia.onduction in the His bundle (Gallagher et al. [31] Schein- san et al. [32], the accessory pathway (Weber and Schmitz
33], the circuit of atrial flutter (Saoudi et al. [34], and the
ite of origin or circuit of ventricular tachycardias (Hartzler
35], Puech et al. [36], and Fontaine et al. [37]. This was
ollowed by the use of radiofrequency current, pioneered by
udde, Breithardt, and Borggrefe (38). Successful outcome
n a large series of patients with supraventricular tachy-
ardias was thereafter reported by Lee et al. (39), Jack-
an et al. (40), and Kuck and Schulter (41), making
atheter ablation one of the few curative treatments in
ardiology.
he rise and fall of antiarrhythmic drugs. Continuous
onitoring of cardiac rhythm in the coronary care unit
rovided us with information about arrhythmias during
ardiac ischemia and their role in life-threatening compli-
ations (42). This also resulted in the concept of so-called
warning arrhythmias” (43) and the use of prophylactic
idocaine (44). Both warning arrhythmias and prophylactic
idocaine did not stand the test of time (45) but influenced
ur thinking about the ventricular premature beat as a target
or pharmacologic prevention of serious ventricular arrhyth-
ias and sudden death.
Before the Cardiac Arrhythmia Suppression Trial
CAST) (46), the treatment of ventricular arrhythmias was
ostly empiric without large controlled studies. Premature
entricular beats were considered to be markers of risk, and
odium channel blockers (quinidine, disopyramide, and
ecainide) were the antiarrhythmic drugs used most com-
only. The CAST study opened our eyes to possible
roarrhythmic effects of antiarrhythmic drugs. It became
lear that antiarrhythmic drugs may kill more people than
hey save. That knowledge came at a time when many of us
the re-entry circuit and causes refractoriness of the tissue in front of theadestill believed that programmed electrical stimulation of the
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Cardiac Arrhythmias: The Quest for a Cure September 15, 2004:1155–63eart could be helpful in selecting the best antiarrhytmic
rug in a patient suffering from an arrhythmia. The
ake-up call from the CAST study made us more critical
bout serial drug testing. It became clear that the assump-
ion that prevention of tachycardia induction by pro-
rammed stimulation might predict long-term efficacy was
orrect in patients with a single re-entry circuit with fixed
lectrophysiologic properties but not in a complex arrhyth-
ia substrate such as a scar after myocardial infarction (Fig.
). The extent of cardiac damage and the degree of
unctional impairment were found to have an inverse
elationship with the ability to find an antiarrhythmic drug
ble to prevent arrhythmia recurrences. Only beta-blocking
gents and amiodarone were able to reduce arrhythmia
ortality in patients with severely diminished left ventric-
lar (LV) function after a myocardial infarction or in
on-ischemic dilated cardiomyopathy (47,48).
HE PRESENT
isk-stratification for sudden death. One of our greatest
roblems is sudden arrhythmic death outside the hospital.
lthough we are putting a lot of effort and money into trying
o identify the person at risk of dying suddenly, only 10% of
udden cardiac arrest victims have a high-risk profile (49,50).
nfortunately, most of the tests shown in Figure 4 alone or in
ombination, have a low positive predictive accuracy, especially
hen decisions have to be made about expensive preventive
reatment such as a defibrillator implant. That decision is easy
n patients resuscitated from circulatory arrest or suffering from
hemodynamically poorly tolerated ventricular arrhythmia
51–53), although the price per year life saved may be expensive
54). More recently, patients have been identified that will
rofit from a defibrillator implant to protect them from sudden
igure 3. Drawing explaining why antiarrhythmic drug studies during
rogrammed stimulation of the heart result in more dependable informa-
ion in supraventricular re-entrant tachycardia (SVT) than in ventricular
achycardia (VT) occurring in a scar after myocardial infarction. In the
achycardia on the left, a fixed tachycardia circuit is present consisting of
trial tissue, the atrioventricular node-His bundle and bundle branches,
entricular tissue, and an accessory atrioventricular connection. This allows
he selection of a drug that blocks conduction in the “weakest” part of the
ircuit. In contrast, in the scar after myocardial infarction, VT usually has
everal possible reentry circuits that, because of differences in size and
lectrophysiologic properties, are affected differently by antiarrhythmic
rugs.rrhythmic death. They are characterized by having a poor LV runction with or without non-sustained ventricular arrhyth-
ias and with coronary or noncoronary heart disease (55–59).
ost-effectiveness analysis of these studies suggested a cost of
16,000 to $22,000 per year of life saved for Multicenter
utomatic Defibrillator Implantation Trial (MADIT) I (55)
nd Multicenter UnSustained Tachycardia Trial (MUSTT)
56), an extremely cost-effective result (54). Earlier termination
f the MADIT II (57) made the cost-effectiveness in that
tudy much less (around $150,000 per year of life saved). That
nding from MADIT II, which will probably also be the case
n the Sudden Cardiac Death in Heart Failure Trial (SCD-
eFT) (58) population makes it mandatory to look for better
ays to select patients that should receive an implantable
efibrillator for the primary prevention of an arrhythmic death.
his requires that several aspects should be studied, such as the
RS width, presence of T-wave alternans, value of ventricular
achycardia induction during electrophysiologic study, size and
ocation of a postmyocardial infarction scar, New York Heart
ssociation functional class, and heart rate turbulence to fine
une the selection of the implantable cardioverter defibrillator
ecipient to make this financially affordable.
F. As pointed out a decade ago (59), AF is the last big
urdle in treating supraventricular tachycardias. Currently,
n the U.S. 2.5 million suffer from AF, and that number is
redicted to double in the next 35 years. Atrial fibrillation
ncreases mortality two-fold and is found in one-third of the
atients above the age of 65 years who suffered a stroke.
TRIAL REMODELING. During the last decade, new infor-
ation has become available about the effect of AF on
lectrical, structural, and functional properties of atrial tissue
60–62). It was shown that, during AF, the refractory
eriod shortens and looses its rate-related behavior. This
ccurred in a non-uniform way, increasing disparity in
igure 4. Risk stratification after myocardial infarction (MI). BNP brain
atriuretic peptide; CRP C-reactive protein; ECG electrocardiogram;
PS  electrophysiologic study; LV  left ventricle; LVEF  left
entricular ejection fraction; MIBG  meta-iodobenzylguanidine; NYHA
New York Heart Association.efractory period duration. Also, conduction velocity in the
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September 15, 2004:1155–63 Cardiac Arrhythmias: The Quest for a Curetrium slowed. All of these changes promote the recurrence
nd persistence of AF. Reversibility of these changes was
ound to depend upon the duration of AF and presence of
ardiac disease resulting in factors such as stretch of atrial
bers and increased fibrosis formation in the atrial wall.
ATHETER ABLATION. It was found that ectopic impulse
ormation in or around the pulmonary veins plays an
mportant role in the initiation and maintenance of parox-
smal AF (63). That observation resulted in catheter abla-
ive approaches originally inside (64,65), and later around,
he pulmonary veins, with or without additional atrial
blation lines. Short-term efficacy of catheter approaches
as been demonstrated, more so in paroxysmal than in
ersistent AF. There are still questions about the end point
f catheter ablation, both at the end of the catheterization
complete isolation of pulmonary veins (66), termination of
F during ablation, prevention of re-initiation of AF) and
ong term (no AF or less AF during follow-up, symptomatic
r nonsymptomatic AF, no recurrences without or with
ntiarrhythmic drugs, and effect of ablation on cardiac
unction).
It is also not clear what ablative approach (radiofre-
uency, cryo, laser, ultrasound, or microwave) is best and
hich one is giving the least number of complications.
andomized studies comparing catheter ablation with an-
iarrhythmic drug therapy with a sufficiently long follow are
eeded. At present, cost and duration of the procedure
ake it likely that only a minority of AF patients can be
elped by catheter ablation.
ATE VERSUS RHYTHM CONTROL. In the 1980s and 1990s,
ardiologists tried in most of their AF patients to convert
he arrhythmia by pharmacologic or electrical cardioversion,
nd then to keep them in sinus rhythm by antiarrhythmic
rug therapy. However, the relative inefficacy of antiar-
hythmic drug therapy to prevent recurrences of AF, their
ide effects, the efficacy of anticoagulant therapy to prevent
trokes, and the adequate control of the ventricular rate
uring AF with drug therapy gave rise to the question
hether sinus rhythm should be preferred and repeatedly
ttempted to be restored. Recently, five studies were com-
leted in which rate versus rhythm control of AF was
valuated in regard to mortality, strokes, hospitalizations,
uality-of-life, and costs (67–71). In total, 5,239 patients
ere included. Persistent AF was present in four studies,
nd both persistent and paroxysmal AF in one study (68).
ll-cause mortality in the rate control group was 339 of
,609 13%, and in the rhythm control group 383 of 2,630
14.6% (p  0.08). There were also no significant
ifferences in stroke incidence between rate or rhythm
ontrol. The incidence of sinus rhythm at the end of the
tudy varied from 38.0% to 73.3% in the rhythm control
roup and from 9.0% to 34.6% in the rate control group (not
urprisingly with the highest number in the Atrial Fibrilla-
ion Follow-up Investigation of Rhythm Management (AF-
IRM) study (68) because they also included patients with
aroxysmal AF). These studies suggest that, in general, ahere seems to be no advantage of rhythm control when the
atient with AF is 65 years and older. However, no definite
ata are available as to subgroups such as the young patient
r the patient with heart failure (HF). It did become clear
hat, in patients with a history of AF and risk factors for
troke, anticoagulant therapy should be continued (and
ell-controlled!) also in sinus rhythm.
F. Currently, we are not only witnessing an epidemic of
F but also of HF. Arrhythmic death is a common mode of
eath in HF occurring in approximately half of the cases. In
ecent years, two things have become clear: 1) in patients
ith HF, symptomatic ventricular arrhythmias and syncope
redict an increased risk of sudden death, but that is not the
ase when asymptomatic ventricular arrhythmias are present
72); and 2) in HF patients drugs that were not developed
s antiarrhythmic drugs such as beta-blockers, angiotensin-
onverting enzyme inhibitors, angiotensin II receptor block-
rs, statins, aldosterone receptor antagonists, polyunsatu-
ated fatty acids, and aspirin are more effective in reducing
rrhythmic death in HF than antiarrhythmic drugs (73).
he SCD-HeFT study (74) suggests that, in patients with
F, the presence of New York Heart Association functional
lass II or III and a LV ejection fraction of 35% are
arkers for selecting HF patients who may profit from an
CD implant. But as discussed earlier, to make this finan-
ially affordable, further fine-tuning in selecting implantable
ardioverter defibrillator candidates is required.
ardiac resynchronization therapy. Almost 25 years ago,
pidemiologic studies indicated that the presence of left
undle branch block (LBBB) predicted a shorter life span
75,76). Grines et al. (77) showed that isolated LBBB
esulted in interventricular asynchrony. Endocardial map-
ing studies in patients with LBBB (78) indicated that the
igure 5. Examples of right and left ventricular activation in left bundle
ranch block. In panel A, septal breakthrough of the activation front
oming from the right ventricle occurs in the superior part of the
ntraventricular septum. This results in desynchronized contraction of both
entricles with the right ventricle contracting in an apicobasal direction and
he left ventricle in a basoapical direction. In panel B, septal breakthrough
akes place in the inferior portion of the intraventricular septum. Right and
eft ventricular contraction is desynchronized but occurs in both in
picobasal direction.ctivation sequence of the left ventricle may vary consider-
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Cardiac Arrhythmias: The Quest for a Cure September 15, 2004:1155–63bly resulting, as shown in Figures 5 and 6, in different
atterns of LV contraction and degree of mitral incompe-
ence. In LBBB, the degree of QRS widening is a predictor
f life expectancy (79). When it was shown that permanent
acing was possible with transvenous leads inserted into the
oronary veins (80), studies were started to evaluate the
ffect of biventricular pacing to restore resynchronization of
entricular contraction in patients with intraventricular and
nterventricular conduction disturbances and HF (81). It
as found that resynchronization of ventricular activation
y LV pacing with or without synchronized right ventricular
acing in patients with LV electromechanical dyssynchrony
usually caused by LBBB) resulted in improvement in
xercise tolerance, well-being, ventricular performance, a
ecrease in hospitalizations, a decrease in neurohumoral
ctivity, and a decrease in death (82). Unfortunately, about
0% of HF patients with ventricular electromechanical
yssynchrony do not respond to pacing-regulated resyn-
hronization of ventricular activation. As shown in Table 1,
here are still many questions that need to be answered to
ptimize the selection of patients profiting from cardiac
esynchronization therapy.
igure 6. A cross-section of the right ventricle (RV) and left ventricle (L
f septal breakthrough may affect desynchronized contraction of the two p
esynchronization of the PMs is most marked in posteroseptal breakthro
reakthrough (panel B).
able 1. Questions in CRT
1. How to select the responder?
a. By measuring LV electromechanical dyssynchrony?
b. RV size and function?
c. Ventricular arrhythmias ( ICD)?
d. BNP value?
2. How to select the appropriate pacing site(s) and pacing (AV and
LV–RV) intervals?
3. Role of CRT in atrial fibrillation and conventionally paced patients?
4. Impact on mortality?
5. Cost-effectiveness?
6. Preventive application in patients with electromechanical
dyssynchrony but in NYHA functional class I or II heart failure?
V  atrioventricular; BNP  brain natrivretic peptide; CRT  cardiac resychroni-
ation therapy; ICD  implantable cardioverter defibrillator; LV  left ventricular;
YHA  New York Heart Association; RV  right ventricular.enetic arrhythmology. During the last decade, it became
ossible to make a genetic diagnosis in patients who have
ertain ECG features. That has been of help in risk-
tratification and management of carriers of monogenic
iseases prone to cardiac arrhythmias and sudden death
Table 2). The current impression is that the ECG has high
pecificity but low sensitivity because of marked differences
n phenotypic expression (83). The experience in the long
T syndrome and the Brugada syndrome indicates that the
CG can be helpful in making decisions about management
84,85).
HE FUTURE
ardiac arrhythmias will continue to be present in the
oming years. But new developments will allows us to
ontrol them better and possibly cure them in an increasing
umber of patients. Device therapy will increase. It is
xpected that in 2006 the number of implanted cardioverter
efibrillators will double those in 2003, raising the question
f how to control this rapidly growing implantable cardio-
erter defibrillator population. Will wireless home monitor-
ng and reprogramming be the solution?
The MADIT II (86) and the Defibrillator in Acute
the horizontal plane. As shown during left bundle branch block, the site
y muscles (PMs) resulting in mitral incompetence. As shown in panel A,
More synchronized activation of the PMs occurs in case of anteroseptal
able 2. Familial Diseases With a Monogenetic Basis for
ardiac Arrhythmias and Sudden Death
yperthrophic cardiomyopathy
ilated cardiomyopathy
ong-QT syndrome
hort-QT syndrome
rugada syndrome
atecholaminergic polymorphic ventricular tachycardia
rrhythmogenic right ventricular dysplesia
olff-Parkinson-White syndrome
trial fibrillation
ick sinus syndrome
trioventricular block
yotonic dystrophyV) in
apillar
ugh.
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September 15, 2004:1155–63 Cardiac Arrhythmias: The Quest for a Cureyocardial Infarction Trial (DINAMIT) (87) study sug-
est that implantable cardioverter defibrillator shocks may
ccelerate the progression of HF. This may lead to an
ncreased use of antiarrhythmic drugs to diminish the
umber of shocks and to facilitate termination of ventricular
achycardia by antitachycardia pacing (88). Cell transplan-
ation to replace damaged or lost myocardial cells will be an
rea of increasing activity. The initial experience with
utologous skeletal myoblasts indicated that arrhythmic
omplication may occur (89,90). That finding is not sur-
rising because the myoblast is not able to make electrome-
hanical contact with neighboring host cells. So far, stem
ell therapy has not been reported to induce cardiac arrhyth-
ias, but insufficient information is available about the
bility of transplanted stem cells to couple electromechani-
ally among themselves and with host cardiomyocytes (91).
tudies are needed to answer these questions and to estab-
ish when implantable cardioverter defibrillators need to be
mplanted to protect the patient.
In AF, we will see growing interest in the development
nd evaluation of antiarrhythmic drugs specifically binding
o atrial tissue. Another area of research to combat the AF
pidemic is to develop measures that interfere with age-
elated fibrosis formation in the heart, which is an important
actor in promoting AF, conduction disturbances, and
iastolic dysfunction.
Genetic analysis will continue to improve our diagnostic
bilities and will become increasingly helpful in advising
reventive measures. It is also likely that, in the near future,
nformation about our genetic background will facilitate
election of medication and their correct dose (pharmaco-
enomics).
However, it seems that we still have a long way to go
efore gene therapy will be a curative option in patients with
erious arrhythmias. Sudden cardiac arrest out-of-hospital
ill continue to haunt us. In the Western world, one-fifth of
ll deaths occur suddenly and unexpectedly with about half
f the cases having cardiac arrest as the first manifestation of
eart disease. With our current efforts including wide
istribution of automatic external defibrillators, the number
f victims successfully resuscitated remains small.
As indicated earlier (92), a crucial step in the manage-
ent of this problem could be the development of wearable
evices reliably able to recognize cardiac arrest, making an
udible alarm, and transmitting the location of the victim to
he site of the nearest automatic external defibrillator and
dvanced life support team.
onclusions. As in other subspecialties in cardiology, im-
ortant progress has been made in the diagnosis and
reatment of cardiac arrhythmias during the last four de-
ades. In this review we looked at the past and discussed the
resent. The conclusion is that, in spite of many advances,
e are at present only able to really cure cardiac arrhythmias
nd to prevent sudden arrhythmic death in a minority of our
atients. New developments are needed to bring us better
esults in the future.cknowledgments and apology
lease see the September 15 issue of JACC at www.
ardiosource.com/jacc.html.
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